

South Carolina  
**Department of Health and Human Services**  
Post Office Box 8206  
Columbia, South Carolina 29202-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**August 7, 2019**  
**MINUTES**

**1. Call to Order**

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, August 7, 2019.

**2. Welcome**

Thomas Phillips, RPh, called the meeting to order and welcomed members, guests, and staff members.

Mr. Phillips opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

**3. Committee Members Present:**

Tan Platt, MD  
Philip Mubarak, MD  
Cheryl Hartvigsen, RPh

Thomas Phillips, RPh  
Duncan Norton, MD  
Kimberly Rudd, MD

Joni Bolinger, MD  
Erika Tillery, PharmD  
Kenric Ware, PharmD

**SC DHHS Staff:**

Jim Bradford, MD  
William Wynn, PharmD  
Constance Holloway, JD  
Janet Giles

**Magellan Medicaid Admin:**

Lisa Correll, PharmD  
Lori Ash

**4. Discussion Topics**

**A. Committee Meeting Minutes, Wednesday, May 8, 2019**

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

**B. Public Comment**

Company	Speaker	Drug/Class
Novartis	Joseph Dye, PhD, RPh	Aimovig®
Teva	Paul Isikwe, PharmD	Ajovy®
Eli Lilly	Jennifer Ward, RN, BSN	Emgality®
Abbott	Andrew Weiss, PharmD	Abbott Freestyle Libre
Dexcom, Inc.	Roy Thomas, PharmD	Dexcom G6
Medtronic	Steve Stagliano	Medtronic Guardian Connect

**C. Drug Classes for Review**

Lisa Correll led the discussion for the following drug classes:

*Classes for Review*

- Anti-CGRP (Calcitonin Gene-related Peptide) Migraine Treatment
- Continuous Glucose Monitors (stand alone/no pump)

The chart below represents the recommendations from the P & T Committee:

<b>ANTI-CGRP (CALCITONIN GENE-RELATED PEPTIDE) MIGRAINE TREATMENT</b>	
Preferred	Non-Preferred
Emgality 120mg pen/syringe‡	Aimovig 70/140mg syringe Ajovy 225mg syringe
<b>CONTINUOUS GLUCOSE MONITORS</b>	
Preferred	Non-Preferred
Freestyle Libre‡ Dexcom G6‡	Medtronic Guardian Connect

‡ Indicates “Added as Preferred”

+ Indicates “Moved to Non-Preferred”

**5. Old Business**

None

**6. New Business**

Lisa provided an overview of new drugs to market. William provided updates for the following items effective July 1, 2019: 340B, final action for Autism Spectrum Disorder (ASD) rate setting methodology, final action for the incorporation of institutions for mental diseases and opioid treatment program (OTP) clinics in the coordinated care benefit, pediatric and preventative (PPB)

benefit enhancements, provider payments – reimbursement methodology modernization, dental benefit alignment and the 1115 Demonstration Waiver which is in Q&A session with CMS. SC DHHS is still awaiting a CMS response on the Preconception Care model waiver.

**7. Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

*Classes for Review*

Anti-CGRP (Calcitonin Gene-related Peptide) Migraine Treatment  
Continuous Glucose Monitors (stand alone/no pump)

**8. Closing Comments**

The next meeting will be held on Wednesday, November 6, 2019.

**9. Adjournment**

The meeting adjourned at 5:35 p.m.